Synergistic therapy with cerium-based nanozymes and mitochondrial RNA polymerase inhibition combats mitochondrial double-stranded RNA-mediated inflammation in osteoarthritis | Synapse
March 3, 2026
Synergistic therapy with cerium-based nanozymes and mitochondrial RNA polymerase inhibition combats mitochondrial double-stranded RNA-mediated inflammation in osteoarthritis
Key Points
Reduced inflammation is observed with the combined therapy of cerium-based nanozymes and RNA polymerase inhibition, leading to effective treatment conditions.
A key finding indicates a significant decrease in double-stranded RNA-mediated inflammation in osteoarthritis models, particularly those treated with the synergistic therapy.
The approach includes a targeted inhibition of mitochondrial RNA polymerase alongside the application of nanozymes to improve therapy effectiveness.
This combined therapeutic strategy may enable better management of osteoarthritis symptoms, though further studies are necessary for clinical application.